23 May 2024

Julie Londsale-Light

My diagnosis was no secret

Julie Londsale-Light was 41 years old when she started experiencing symptomsof MS. Concerned, Julie visited her doctor about her symptoms, and was sent for a CATSCAN, MRI and a lumbar puncture to investigate further.  

“The diagnosis process took approximately six weeks in total. But because I was living in a small regional town, I experienced some difficulty in travelling long distances to see a neurologist and attend all my appointments.” 

Looking back, Julie says there were other symptoms which she had dismissed as other things.  

“I knew very little at all about MS and have no family history.” 

Despite the challenges and obstacles Julie faced prior to and following her diagnosis, she felt totally supported, and says she made no secret of what she was going through. 

“All the medical staff were wonderful and caring. I felt able to ask any questions and was also given a wealth of information to access in my own time. I was supported by my family and work, MS Queensland, MS Nurse through Biogen, my local MS Facebook group, NDIS, a Support Worker, counsellor, physiotherapist and occupational therapist, and many more individuals.”  

Julie Lonsdale-Light is a member of the Lived Experience Expert Panel (LEEP), which brings a wide range of lived experience and expertise to the work of MS Australia. Read more about the LEEP here.

World MS Day, acknowledged on May 30, is a day that fosters global unity and optimism. The 2024-2025 theme ‘Diagnosis’ and ‘My MS Diagnosis’ campaign, advocates for timely and accurate identification of multiple sclerosis (MS). The campaign shares real experiences and urges improved healthcare professional training, research, and clinical progress for MS diagnosis.  

World MS Day is an opportunity to share stories, like this one, raise awareness and campaign with everyone affected by MS.  #MyMSDiagnosis. 

14 January 2025

As we take our first steps into 2025, let’s take a moment to look back at ten of the biggest…

6 January 2025

In a groundbreaking development, the PBAC has recommended listing ravulizumab (Ultomiris®) on the PBS for adults with NMOSD, marking a…

What us to keep you in the loop? Subscribe today!

  • Enter your details

Read More

Newsletter subscription

  • Enter your details

Julie Londsale-Light